1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 22,400 | 22,600 | 02.04. | |
| 21,800 | 23,000 | 02.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.03. | Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum | 1 | GlobeNewswire (USA) | ||
| 17.02. | Anbio Biotechnology - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 26.01. | Anbio Biotechnology - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 30.12.25 | Anbio Biotechnology - 6-K, Report of foreign issuer | - | SEC Filings | ||
| ANBIO BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 09.08.25 | Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System | 203 | GlobeNewswire (Europe) | FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering... ► Artikel lesen |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORGANIGRAM GLOBAL | 1,220 | +1,67 % | Organigram Global Inc.: Organigram Announces Shareholder Approval of Acquisition of Sanity Group GmbH and Results of its Annual General and Special Meeting | Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), is pleased to announce that the shareholders of Organigram have overwhelmingly approved the resolution required to... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 24,800 | -1,98 % | Assembly Biosciences: "Wir erwarten ein weiteres starkes Jahr" | Der Virologieforscher Assembly Biosciences blickt nach einem entscheidenden Jahr 2025 auf eine positive Zukunft. Im jüngsten Geschäftsbericht wird eine Ausweitung der Pipeline angedeutet. Es könnte... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 146,25 | +0,10 % | Axsome Inks Agreement To Obtain Exclusive Global Rights To TAK-063 From Takeda | TOKYO (dpa-AFX) - Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced Wednesday that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063... ► Artikel lesen | |
| COMPASS PATHWAYS | 5,000 | 0,00 % | 3 Psychedelika-Aktien im Fokus: Bioxyne baut operatives Fundament, während Compass Pathways und MindMed klinische Meilensteine anpeilen | ||
| ACHIEVE LIFE SCIENCES | 2,795 | 0,00 % | Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British... ► Artikel lesen | |
| ALTIMMUNE | 2,861 | -1,07 % | Altimmune, Inc: Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH | GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 3,520 | -1,81 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,284 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 30.03.2026 | The following instruments on XETRA do have their first trading 30.03.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 30.03.2026
Aktien
1 SE0008091573 Bonava AB AB
2 SE0007184189... ► Artikel lesen | |
| KALA BIO | 0,143 | -3,71 % | KALA BIO, Inc.: Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities | TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company at the forefront of artificial intelligence and cell and gene therapy innovation... ► Artikel lesen | |
| SCYNEXIS | 0,763 | -0,91 % | Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million | PXL770, a first-in-class direct activator of adenosine monophosphate-activated protein kinase (AMPK), is a clinical-stage drug candidate targeting the underlying mechanisms of autosomal dominant... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 6,450 | +2,38 % | Wave Life Sciences Ltd.: Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following ... | At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p WVE-007 led to greater improvement in... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,140 | -0,93 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 3,240 | +5,19 % | IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock? | ||
| MINDWALK | 0,980 | -1,51 % | Highflyer der Zukunft - "Must Have" für ihr Biotech-Depot?! | ||
| XERIS BIOPHARMA | 5,160 | -1,43 % | Barclays reiterates Xeris Pharmaceuticals stock rating on sales outlook |
ANBIO BIOTECHNOLOGY gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 22,600 Euro und damit +0,89 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANBIO BIOTECHNOLOGY finden Sie auf Wallstreet Online.